Rodman & Renshaw initiated coverage of Athira Pharma with a Buy rating and $22 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHA:
- ATHA Earnings this Week: How Will it Perform?
- Athira Pharma reports Q2 EPS (70c), consensus (74c)
- Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
- Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
- Athira Pharma presents preclinical data on fosgonimeton at AAIC